Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157
Mountain Valley MD reports advancement of its Quicksome sublingual delivery platform, completing initial formulation work for multiple peptides including BPC-157, GHK-Cu, and retatrutide. The company emphasizes that Quicksome is a delivery technology, not a drug developer, and does not own rights to the underlying peptide molecules. It aims to license the platform to compounding pharmacies to enable needle-free, room-temperature stable administration.
Key figures
- Market cagr
- 8.7%
- Glp1 revenue 2024
- $46 billion
- Cold chain stability temp
- 40 degrees Celsius
- Global peptide market 2025
- $141 billion
- Global peptide market 2033
- $295 billion
- Cold chain preservation rate
- 100%
- Cold chain stability duration
- 5 days
- Retatrutide revenue projection 2031
- $15 billion to $30 billion
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.